Peptide Association
Start Your Consultation
All peptides
OncologyFDA Approved

Degarelix (Firmagon)

Subcutaneous injection
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Degarelix is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of advanced prostate cancer. Unlike GnRH agonists, degarelix competitively blocks GnRH receptors in the anterior pituitary without causing an initial testosterone surge, achieving rapid suppression of luteinizing hormone and testosterone.

Mechanism of Action

This immediate pharmacological castration provides therapeutic benefit in androgen-dependent malignancies. The peptide consists of unnatural amino acids to resist enzymatic degradation and prolong activity.

Research Summary & Key Findings

Degarelix received FDA approval in 2008 based on phase 3 trials demonstrating non-inferiority to leuprolide in maintaining castrate testosterone levels, with superior suppression of follicle-stimulating hormone. A cardiovascular substudy published in BMJ Open (2014) suggested a potential advantage in reducing cardiovascular events compared to GnRH agonists, though this remains an area of ongoing investigation. The CS21 trial established its efficacy in maintaining testosterone suppression over 12 months.

Clinical Status

FDA Approved

Degarelix (Firmagon) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Oncology

Carfilzomib (Kyprolis)

FDA Approved

A tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...

View details

Bortezomib (Velcade)

FDA Approved

A modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...

View details

Lutetium-177 dotatate (Lutathera)

FDA Approved

A radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...

View details

Leuprolide (Lupron) - Oncology

FDA Approved

A GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...

View details

Start Your Consultation

Get an AI-proposed Degarelix (Firmagon) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Degarelix (Firmagon).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.